Low-dose ranibizumab administration in retinopathy of prematurity

Purpose To evaluate the efficiency of low-dose intravitreal ranibizumab therapy in the treatment of aggressive retinopathy of prematurity (A-ROP). Methods A total of 124 eyes of 62 patients who underwent intravitreal ranibizumab after an A-ROP diagnosis between January 2015 and January 2021 were eva...

Full description

Saved in:
Bibliographic Details
Published in:International ophthalmology 2022-05, Vol.42 (5), p.1545-1552
Main Authors: Tök, Levent, Seyrek, Lütfi, Yalçın Tök, Özlem
Format: Article
Language:English
Subjects:
Babies
Birth weight
Disease
Drug dosages
Eye
Eye (anatomy)
Gestational age
Hospitals
Informed consent
Injection
Iodine
Lasers
Medicine
Medicine & Public Health
Monoclonal antibodies
Ophthalmology
Original Paper
Patients
Physiology
Retinopathy
Sheep
Side effects
Vascular endothelial growth factor
Vascularization
Visual field
Visual fields
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose To evaluate the efficiency of low-dose intravitreal ranibizumab therapy in the treatment of aggressive retinopathy of prematurity (A-ROP). Methods A total of 124 eyes of 62 patients who underwent intravitreal ranibizumab after an A-ROP diagnosis between January 2015 and January 2021 were evaluated retrospectively. After receiving family-approved informed consent, low-dose intravitreal ranibizumab was administered, and regular follow-ups were performed. Results Patients included in the study had a mean birth week of 26.6 (23–33 weeks), a mean birth weight of 905 (450–1970) grams, and an average injection postnatal time of 9.1 (4–19) weeks. The mean follow-up period was 63 (24–250) weeks. In all eyes, ROP regressed in the first week after injection, and no asymmetrical response was observed in the eyes of any baby. A total of 58 eyes recovered with a single dose of intravitreal injection therapy, and peripheral retinal vascularization was completed. A second injection was required in 38 eyes. Rescue treatment was applied in addition to intravitreal ranibizumab treatment in 22 eyes of 11 babies. None of the patients had any ocular or systemic side effects. Conclusion Low-dose intravitreal ranibizumab injection with close follow-up and appropriate timing is an effective treatment modality in A-ROP. Even among patients undergoing rescue laser treatment, the treatment can be completed with a wide visual field.
ISSN:1573-2630
0165-5701
1573-2630
DOI:10.1007/s10792-021-02145-w